ClinicalTrials.gg
CompletedNCT00493220INFUSE-CftrxUpdated Dec 2, 2011Results posted

Pharmacokinetic and Safety Study of HYLENEX Recombinant-Augmented Subcutaneous Ceftriaxone Administration

A Phase 1 interventional study of SC HYLENEX and Ceftriaxone and SC Placebo and Ceftriaxone in Healthy, sponsored by Baxter Healthcare Corporation. Completed. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-12-02.

Sponsored by Baxter Healthcare Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The objectives of this study are:

  • to establish the safety of subcutaneous administration of ceftriaxone at different concentrations, with and without HYLENEX recombinant, and to determine the maximum tolerated concentration;
  • and to establish the pharmacokinetic comparability of subcutaneous administration of ceftriaxone with HYLENEX recombinant to subcutaneous administration without HYLENEX recombinant and to IV administration.
02

Conditions studied

  • Healthy

Keywords

  • ceftriaxone
  • cephalosporins
  • pharmacokinetics
  • subcutaneous
  • hyaluronoglucosaminidase
  • hyaluronidase
  • hyaluronan
  • rHuPH20
03

In context

Lead sponsor

Baxter Healthcare Corporation is the lead sponsor of 80 studies on the registry; 1 is open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18-65 years of age
  • If female: non-lactating; non-pregnant; and incapable of becoming pregnant, or taking specific precautions to avoid becoming pregnant before and during study
  • Normal clinical laboratory parameters
  • Adequate venous access in both upper extremities
  • Agreeing to refrain from smoking and from ingesting any alcohol or caffeine-containing products before and during the study
  • Good health based on medical history, physical examination and laboratory tests
  • Non-smoking; or smoking less than 10 cigarettes per day and willing to refrain from use of nicotine products before and during study

Exclusion criteria

Exclusion Criteria:

  • Received a cephalosporin within the 21 days prior to study or anticipated to receive non-study cephalosporin during study
  • Pregnant or breast-feeding.
  • Previously exposed to a hyaluronidase drug product
  • Medical condition presenting unacceptable safety risk or likely to prevent completion of study
  • Known to hyaluronidase or any other ingredient in HYLENEX recombinant
  • to ceftriaxone, including known allergy to beta-lactam antibiotics
  • Local condition precluding subcutaneous injection or injection site evaluation
  • History of gastrointestinal disease (in particular colitis)
  • Consumption of caffeine- or other methylxanthine-containing beverage within 24 hours before and/or during the PK sampling period
  • Participation in study of any drug or device within 30 days before this study
  • Serum \<12 g/dL.
  • Blood donation or significant loss of blood within 56 days, or plasma donation within 7 days, prior to study
  • Medical history/condition, screening physical examination finding or clinical laboratory result precluding safe participation in study, or which might adversely effect interpretation of study results
  • History of drug or alcohol abuse within 2 years prior to study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    HYLENEX SC, Placebo SC, IV

    subcutaneous HYLENEX and ceftriaxone as 1st intervention, subcutaneous placebo and ceftriaxone as 2nd intervention, IV ceftriaxone as 3rd intervention

    Drug: SC HYLENEX and Ceftriaxone · Drug: SC Placebo and Ceftriaxone · Drug: IV Ceftriaxone

  • Experimental
    HYLENEX SC, IV, Placebo SC

    subcutaneous HYLENEX and ceftriaxone as 1st intervention, IV ceftriaxone as 2nd intervention, subcutaneous placebo and ceftriaxone as 3rd intervention

    Drug: SC HYLENEX and Ceftriaxone · Drug: SC Placebo and Ceftriaxone · Drug: IV Ceftriaxone

  • Experimental
    Placebo SC, HYLENEX SC, IV

    subcutaneous placebo and ceftriaxone as 1st intervention, subcutaneous HYLENEX and ceftriaxone as 2nd intervention, IV ceftriaxone as 3rd intervention

    Drug: SC HYLENEX and Ceftriaxone · Drug: SC Placebo and Ceftriaxone · Drug: IV Ceftriaxone

  • Experimental
    Placebo SC, IV, HYLENEX SC

    subcutaneous placebo and ceftriaxone as 1st intervention, IV ceftriaxone as 2nd intervention, subcutaneous HYLENEX and ceftriaxone as 3rd intervention

    Drug: SC HYLENEX and Ceftriaxone · Drug: SC Placebo and Ceftriaxone · Drug: IV Ceftriaxone

  • Experimental
    IV, HYLENEX SC, Placebo SC

    IV ceftriaxone as 1st intervention, subcutaneous HYLENEX and ceftriaxone as 2nd intervention, subcutaneous placebo and ceftriaxone as 3rd intervention

    Drug: SC HYLENEX and Ceftriaxone · Drug: SC Placebo and Ceftriaxone · Drug: IV Ceftriaxone

  • Experimental
    IV, Placebo SC, HYLENEX SC

    IV ceftriaxone as 1st intervention, subcutaneous placebo and ceftriaxone as 2nd intervention, subcutaneous HYLENEX and ceftriaxone as 3rd intervention

    Drug: SC HYLENEX and Ceftriaxone · Drug: SC Placebo and Ceftriaxone · Drug: IV Ceftriaxone

Interventions

  • DrugSC HYLENEX and Ceftriaxone

    Drug page: Hyaluronoglucosaminidase

    single, subcutaneous, 150 U dose of HYLENEX; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)

    Also known as: HYLENEX recombinant, hyaluronoglucosaminidase, hyaluronidase, rHuPH20

  • DrugSC Placebo and Ceftriaxone

    single, subcutaneous injection of 1 mL 0.9% sodium chloride solution; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)

    Also known as: saline, normal saline, 0.9% sodium chloride injection

  • single, intravenous infusion of 1 gm ceftriaxone (40 mg/mL solution administered at 0.83 mL/min over 30 minutes)

    Also known as: ceftriaxone

06

What researchers measure

Primary outcomes

  1. AUC0-t

    Area under the drug concentration-time curve from time zero to the time of the last measurable concentration (calculated by the linear trapezoidal method)

    Time frame: Start of ceftriaxone administration through time of last measureable plasma ceftriaxone concentration

  2. AUC0-inf

    Area under the drug concentration-time curve from time zero to infinity, calculated as AUC0-t + Ct/kel (Ct = time of last measurable concentration; kel = terminal elimination rate constant)

    Time frame: from the start of ceftriaxone administration to infinity

Secondary outcomes

  1. Cmax

    Maximum measured plasma ceftriaxone concentration

    Time frame: at the time of the highest measured plasma ceftriaxone concentration

  2. Tmax

    Time to maximum measured plasma ceftriaxone concentration

    Time frame: from start of ceftriaxone administration until time of maximum measured plasma ceftriaxone concentration

07

Results

Posted Dec 2, 2011

Participant flow

Healthy volunteers recruited via subject-initiated telephone or internet contacts or visits to Phase I unit. Those considered potentially eligible were, after obtaining consent, screened in detail to determine eligibility against protocol eligibility criteria.

First Intervention
Participant flow — First Intervention
MilestoneHYLENEX SC, Placebo SC, IVHYLENEX SC, IV, Placebo SCPlacebo SC, HYLENEX SC, IVPlacebo SC, IV, HYLENEX SCIV, HYLENEX SC, Placebo SCIV, Placebo SC, HYLENEX SC
Started555555
Completed555555
Not completed000000
First 7-Day Washout & Safety Follow-up
Participant flow — First 7-Day Washout & Safety Follow-up
MilestoneHYLENEX SC, Placebo SC, IVHYLENEX SC, IV, Placebo SCPlacebo SC, HYLENEX SC, IVPlacebo SC, IV, HYLENEX SCIV, HYLENEX SC, Placebo SCIV, Placebo SC, HYLENEX SC
Started555555
Completed555555
Not completed000000
Second Intervention
Participant flow — Second Intervention
MilestoneHYLENEX SC, Placebo SC, IVHYLENEX SC, IV, Placebo SCPlacebo SC, HYLENEX SC, IVPlacebo SC, IV, HYLENEX SCIV, HYLENEX SC, Placebo SCIV, Placebo SC, HYLENEX SC
Started555555
Completed555555
Not completed000000
Second 7-Day Washout & Safety Follow-up
Participant flow — Second 7-Day Washout & Safety Follow-up
MilestoneHYLENEX SC, Placebo SC, IVHYLENEX SC, IV, Placebo SCPlacebo SC, HYLENEX SC, IVPlacebo SC, IV, HYLENEX SCIV, HYLENEX SC, Placebo SCIV, Placebo SC, HYLENEX SC
Started555555
Completed555555
Not completed000000
Third Intervention
Participant flow — Third Intervention
MilestoneHYLENEX SC, Placebo SC, IVHYLENEX SC, IV, Placebo SCPlacebo SC, HYLENEX SC, IVPlacebo SC, IV, HYLENEX SCIV, HYLENEX SC, Placebo SCIV, Placebo SC, HYLENEX SC
Started555555
Completed455555
Not completed100000
Withdrew: Withdrawal by subject100000
Final 7-Day Safety Follow-up
Participant flow — Final 7-Day Safety Follow-up
MilestoneHYLENEX SC, Placebo SC, IVHYLENEX SC, IV, Placebo SCPlacebo SC, HYLENEX SC, IVPlacebo SC, IV, HYLENEX SCIV, HYLENEX SC, Placebo SCIV, Placebo SC, HYLENEX SC
Started455555
Completed455555
Not completed000000

Outcome measures

SecondaryCmax

Maximum measured plasma ceftriaxone concentration

Time frame:
at the time of the highest measured plasma ceftriaxone concentration
Reported as:
Mean · µg/mL
Cmax
µg/mLHYLENEX SCPlacebo SCIntravenous
Cmax92.0 ± 15.182.2 ± 13.5150 ± 19.9
Statistical analysis
  • HYLENEX SC vs Placebo SC · Schuirmann two one-sided tests procedure · Lsm ratio (natural log-transformed): 111.79 · 90% CI 108.57 to 115.12HYLENEX SC/Placebo SC
  • HYLENEX SC vs Intravenous · Schuirmann two one-sided tests procedure · Lsm ratio (natural log-transformed): 60.81 · 90% CI 59.06 to 62.62HYLENEX SC/Intravenous
  • Placebo SC vs Intravenous · Schuirmann two one-sided tests procedure · Lsm ratio (%; ln-transformed): 54.40 · 90% CI 52.82 to 56.01Placebo SC/Intravenous
SecondaryTmax

Time to maximum measured plasma ceftriaxone concentration

Time frame:
from start of ceftriaxone administration until time of maximum measured plasma ceftriaxone concentration
Reported as:
Median · hr
Tmax
hrHYLENEX SCPlacebo SCIntravenous
Tmax2.02 (1.02 to 3.01)3.02 (1.52 to 4.04)0.502 (0.501 to 0.611)
Statistical analysis
  • HYLENEX SC vs Placebo SC · Wilcoxon signed-rank test · p = <0.01 · Median difference (net): -1.00 · 90% CI -1.25 to -0.75HYLENEX SC minus Placebo SC
  • HYLENEX SC vs Intravenous · Wilcoxon signed-rank test · p = <0.01 · Median difference (net): 1.52 · 90% CI 1.27 to 1.71Placebo SC minus Intravenous
  • Placebo SC vs Intravenous · Wilcoxon signed-rank test · p = <0.01 · Median difference (net): 2.52 · 90% CI 2.26 to 2.76Placebo SC minus Intravenous
PrimaryAUC0-t

Area under the drug concentration-time curve from time zero to the time of the last measurable concentration (calculated by the linear trapezoidal method)

Time frame:
Start of ceftriaxone administration through time of last measureable plasma ceftriaxone concentration
Reported as:
Mean · μg*hr/mL
AUC0-t
μg*hr/mLHYLENEX SCPlacebo SCIntravenous
AUC0-t1139.3 ± 200.301115.6 ± 180.551065.3 ± 176.07
Statistical analysis
  • HYLENEX SC vs Placebo SC · Schuirmann two one-sided tests procedure · Lsm ratio (%; ln-transformed): 101.99 · 90% CI 98.95 to 105.12HYLENEX SC/Placebo SC
  • HYLENEX SC vs Intravenous · Schuirmann two one-sided tests procedure · Lsm ratio (%; ln-transformed): 106.79 · 90% CI 103.61 to 110.07HYLENEX SC/Intravenous
  • Placebo SC vs Intravenous · Schuirmann two one-sided tests procedure · Lsm ratio (%; ln-transformed): 104.71 · 90% CI 101.59 to 107.92Placebo SC/Intravenous
PrimaryAUC0-inf

Area under the drug concentration-time curve from time zero to infinity, calculated as AUC0-t + Ct/kel (Ct = time of last measurable concentration; kel = terminal elimination rate constant)

Time frame:
from the start of ceftriaxone administration to infinity
Reported as:
Mean · µg*hr/mL
AUC0-inf
µg*hr/mLHYLENEX SCPlacebo SCIntravenous
AUC0-inf1162.6 ± 210.361141.3 ± 192.861085.8 ± 187.50
Statistical analysis
  • HYLENEX SC vs Placebo SC · Schuirmann two one-sided tests procedure · Lsm ratio (%; ln-transformed): 101.76 · 90% CI 98.64 to 104.98HYLENEX SC/Placebo SC
  • HYLENEX SC vs Intravenous · Schuirmann two one-sided tests procedure · Lsm ratio (%; ln-transformed): 106.95 · 90% CI 103.67 to 110.33HYLENEX SC/Intravenous
  • Placebo SC vs Intravenous · Schuirmann two one-sided tests procedure · Lsm ratio (%; ln-transformed): 105.10 · 90% CI 101.87 to 108.42Placebo SC/Intravenous

Adverse events

Collected over from time of start of intervention administration through 7 days after intervention administered. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HYLENEX SC—0/30 (0%)30/30 (100%)
Placebo SC—0/30 (0%)30/30 (100%)
Intravenous—0/29 (0%)22/29 (75.9%)
Most frequent other events
Most frequent other events
EventHYLENEX SCPlacebo SCIntravenous
Infusion site painGeneral disorders30/3030/309/29
Infusion site swellingGeneral disorders5/3028/301/29
Infusion site erythemaGeneral disorders18/3015/304/29
Infusion site bruisingGeneral disorders2/304/306/29
Infusion site reactionGeneral disorders6/300/300/29
Infusion site anaesthesiaGeneral disorders4/301/300/29
HeadacheNervous system disorders2/303/300/29
Infusion site pruritusGeneral disorders2/300/302/29
Vessel puncture site bruiseGeneral disorders1/302/302/29
Infusion site indurationGeneral disorders2/301/300/29

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)HYLENEX SC, Placebo SC, IVHYLENEX SC, IV, Placebo SCPlacebo SC, HYLENEX SC, IVPlacebo SC, IV, HYLENEX SCIV, HYLENEX SC, Placebo SCIV, Placebo SC, HYLENEX SCTotal
<=18 years0000000
Between 18 and 65 years55555530
>=65 years0000000
Age Continuous
Age Continuous(years)HYLENEX SC, Placebo SC, IVHYLENEX SC, IV, Placebo SCPlacebo SC, HYLENEX SC, IVPlacebo SC, IV, HYLENEX SCIV, HYLENEX SC, Placebo SCIV, Placebo SC, HYLENEX SCTotal
Mean32.2 ± 10.637.6 ± 4.034.2 ± 11.534.8 ± 17.534.8 ± 11.033.2 ± 8.034.5 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)HYLENEX SC, Placebo SC, IVHYLENEX SC, IV, Placebo SCPlacebo SC, HYLENEX SC, IVPlacebo SC, IV, HYLENEX SCIV, HYLENEX SC, Placebo SCIV, Placebo SC, HYLENEX SCTotal
Female1011205
Male45443525
Region of Enrollment
Region of Enrollment(participants)HYLENEX SC, Placebo SC, IVHYLENEX SC, IV, Placebo SCPlacebo SC, HYLENEX SC, IVPlacebo SC, IV, HYLENEX SCIV, HYLENEX SC, Placebo SCIV, Placebo SC, HYLENEX SCTotal
United States55555530
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Harb G, Lebel F, Battikha J, Thackara JW. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers. Curr Med Res Opin. 2010 Feb;26(2):279-88. doi: 10.1185/03007990903432900. PubMed 19947907 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Sep 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2011, 4 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2007
First posted
Jun 28, 2007
Start
Jun 2007
Primary completionActual
Sep 2007
CompletionActual
Sep 2007
Results first posted
Dec 2, 2011
Last update
Dec 2, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00493220
First posted
Jun 28, 2007
Start date
Jun 2007
Primary completion
Sep 2007
Completion
Sep 2007
Results posted
Dec 2, 2011
Last update
Dec 2, 2011

Study contacts

George E Harb, MD
study director · Baxter Healthcare Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Hyaluronoglucosaminidase · Ceftriaxone

Start the discussion